Isolate Data
| Patient | Isolate | Region | Year | Species | Subtype | Source | Clone Method |
| CA629 | CA9975 | U.S. | 1998 | HIV1 | B | Plasma | None |
Treatment History
| Order | Regimen | Weeks |
| 1 | DDI | 52 |
| 2 | AZT+SQV | 313 |
| 3 | 3TC+AZT+IDV | 113 |
| 4 | 3TC+D4T+NFV | 4 |
| 5 | AZT+DDI+RTV+SQV | 17 |
| 6 | 3TC+D4T+NVP | 13 |
| 7 | 3TC+AZT | 9 |
| 8 | 3TC+AZT+IDV | 17 |
| 9 | 3TC+AZT+EFV+IDV+Unknown | 4 |
Protease Sequence
| PIMajorDRMs | PIMinorDRMs | Polys | UnusualMuts |
| M46I, L90M | F53L, G73ST | L10I, L63P, C67F, H69HQ, A71V, I72IM, V77I |
| >CA9975| codons 1-99 PQITLWQRPIVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKIIGGIGGLIKVRQYD QIPIEIFGQKVMSTVLIGPTPVNIIGRNLMTQIGCTLNF |
RT Sequence
| NRTIMajorDRMs | NRTIMinorDRMs | NNRTIMajorDRMs | NNRTIMinorDRMs | Polys | UnusualMuts |
| M41L, D67N, T69D, K70R, T215F | K219Q | K103N, Y181C, G190A | V35I, T39A, K122E, I180V, H208Y, D218E, L228H, V245E, A272P |
| >CA9910| codons 1-276 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALIEICAELEKEGKISKIGPENPYNTPV FAIKKKNSDRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKNKSVTVLDVGDAYFSVPL DEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVV CQYMDDLYVASDLEIGQHRTKIEELRQYLLRWGFFTPEQKHQKEPPFHWMGYELHPDKWT VQPIELPEKDSWTVNDIQKLVGKLNWASQIYPGIKV |
References
| Author | Title | Citation |
| Shulman, NS | Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response. | JAIDS, 2000 |
| Kantor, R | Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy. | AAC, 2002 |
| Wu, TD | Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. | J Virol, 2003 |
| Rhee, SY | HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance. | J Infect Dis, 2005 |